 CAMBRIDGE, England--BUSINESS WIRE--Avacta Group plc AIM: AVCT, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and preCISIONTM platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc AIM: ABC; NASDAQ: ABCM to sell the Groups recently developed SARS-CoV-2 research ELISA Affimer reagents. Avacta has developed Affimer reagents which can be used in a high performance ELISA laboratory test to de 